睿智医药
(300149)
| 流通市值：46.55亿 | | | 总市值：48.85亿 |
| 流通股本：4.75亿 | | | 总股本：4.98亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 816,848,135.12 | 533,797,976.84 | 261,261,312.24 | 970,204,758.8 |
| 营业收入 | 816,848,135.12 | 533,797,976.84 | 261,261,312.24 | 970,204,758.8 |
| 二、营业总成本 | 815,922,997.79 | 513,553,112.14 | 260,328,377.29 | 1,031,638,143.67 |
| 营业成本 | 591,783,360.36 | 378,921,265.51 | 189,559,932.03 | 758,697,970.95 |
| 利息支出 | - | - | - | 0 |
| 手续费及佣金支出 | - | - | - | 0 |
| 退保金 | - | - | - | 0 |
| 赔付支出净额 | - | - | - | 0 |
| 提取保险合同准备金净额 | - | - | - | 0 |
| 保单红利支出 | - | - | - | 0 |
| 分保费用 | - | - | - | 0 |
| 税金及附加 | 3,262,638.7 | 2,125,771.08 | 522,015.54 | 5,363,343.8 |
| 销售费用 | 42,602,703.7 | 25,031,453.84 | 11,246,944.27 | 36,406,561.7 |
| 管理费用 | 131,238,406.62 | 81,833,011.13 | 45,776,422.78 | 167,743,905.79 |
| 研发费用 | 41,853,143.7 | 24,722,034.39 | 12,101,507.4 | 59,550,940.69 |
| 财务费用 | 5,182,744.71 | 919,576.19 | 1,121,555.27 | 3,875,420.74 |
| 其中:利息费用 | 12,569,317.7 | 8,318,536.93 | 300,332.49 | 26,098,678.68 |
| 其中:利息收入 | 7,556,805.19 | 5,413,857.93 | 2,150,370.32 | 12,158,879.85 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -10,500.74 | -15,167.73 | -5,444.83 | -2,296,500 |
| 加:投资收益 | 13,835,351.4 | 12,893,493.74 | 1,941,186.55 | 10,091,924.67 |
| 净敞口套期收益 | - | - | - | 0 |
| 汇兑收益 | - | - | - | 0 |
| 资产处置收益 | 6,273,964.72 | 6,261,722.68 | 6,261,722.68 | 8,433,398.14 |
| 资产减值损失(新) | 317,628.4 | -1,635,582.6 | 1,847,630.6 | -156,882,554.07 |
| 信用减值损失(新) | -16,777,280.28 | -12,808,391.56 | -4,817,206.31 | -29,563,544.47 |
| 其他收益 | 9,364,632.29 | 6,730,733.46 | 3,206,031.52 | 14,813,479.08 |
| 四、营业利润 | 13,928,933.12 | 31,671,672.69 | 9,366,855.16 | -216,837,181.52 |
| 加:营业外收入 | 1,378,500.54 | 917,336.1 | 21,116.01 | 67,255.03 |
| 减:营业外支出 | 557,946.26 | 478,061.71 | 64,301.88 | 14,873,936.51 |
| 五、利润总额 | 14,749,487.4 | 32,110,947.08 | 9,323,669.29 | -231,643,863 |
| 减:所得税费用 | 7,587,430.75 | 6,765,580.85 | 2,700,270.94 | -5,131,547.83 |
| 六、净利润 | 7,162,056.65 | 25,345,366.23 | 6,623,398.35 | -226,512,315.17 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 7,162,056.65 | 25,345,366.23 | 6,623,398.35 | -226,512,315.17 |
| 终止经营净利润 | - | - | - | 0 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 7,091,301.27 | 25,382,118.44 | 6,642,081.65 | -226,474,828.03 |
| 少数股东损益 | 70,755.38 | -36,752.21 | -18,683.3 | -37,487.14 |
| 扣除非经常损益后的净利润 | -14,349,544.18 | 6,792,287.51 | -1,570,969.9 | -235,744,176.17 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.01 | 0.05 | 0.01 | -0.45 |
| (二)稀释每股收益 | 0.01 | 0.05 | 0.01 | -0.45 |
| 八、其他综合收益 | -2,279,583.73 | -374,978.77 | -272,754.98 | 3,689,524.72 |
| 归属于母公司股东的其他综合收益 | -2,279,583.73 | -374,978.77 | -272,754.98 | 3,689,524.72 |
| 九、综合收益总额 | 4,882,472.92 | 24,970,387.46 | 6,350,643.37 | -222,822,790.45 |
| 归属于母公司股东的综合收益总额 | 4,811,717.54 | 25,007,139.67 | 6,369,326.67 | -222,785,303.31 |
| 归属于少数股东的综合收益总额 | 70,755.38 | -36,752.21 | -18,683.3 | -37,487.14 |
| 公告日期 | 2025-10-30 | 2025-08-29 | 2025-04-29 | 2025-04-29 |
| 审计意见(境内) | | | | 标准无保留意见 |